Metagenomi (MGX) Competitors $1.88 -0.05 (-2.59%) Closing price 04:00 PM EasternExtended Trading$1.88 0.00 (-0.27%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, AVIR, MREO, LFCR, DBVT, EDIT, VOR, ANNX, NMRA, and ALMSShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Atea Pharmaceuticals (AVIR), Mereo BioPharma Group (MREO), Lifecore Biomedical (LFCR), DBV Technologies (DBVT), Editas Medicine (EDIT), Vor Biopharma (VOR), Annexon (ANNX), Neumora Therapeutics (NMRA), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Atea Pharmaceuticals Mereo BioPharma Group Lifecore Biomedical DBV Technologies Editas Medicine Vor Biopharma Annexon Neumora Therapeutics Alumis Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Is MRNA or MGX more profitable? Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Metagenomi -257.99%-37.84%-27.15% Does the media favor MRNA or MGX? In the previous week, Moderna had 11 more articles in the media than Metagenomi. MarketBeat recorded 27 mentions for Moderna and 16 mentions for Metagenomi. Moderna's average media sentiment score of 0.80 beat Metagenomi's score of 0.48 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 16 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, MRNA or MGX? Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.05-$3.56B-$7.53-3.37Metagenomi$52.29M1.35-$78.06M-$2.36-0.80 Do institutionals & insiders hold more shares of MRNA or MGX? 75.3% of Moderna shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 17.8% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer MRNA or MGX? Moderna currently has a consensus target price of $42.88, suggesting a potential upside of 69.16%. Metagenomi has a consensus target price of $10.00, suggesting a potential upside of 431.91%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, MRNA or MGX? Moderna has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. SummaryModerna beats Metagenomi on 10 of the 16 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.56M$2.78B$5.76B$9.72BDividend YieldN/A1.67%4.40%4.10%P/E Ratio-0.8022.2230.1925.84Price / Sales1.35748.28473.64122.75Price / CashN/A26.0925.7828.79Price / Book0.305.529.425.99Net Income-$78.06M$31.83M$3.27B$265.29M7 Day Performance-2.08%1.08%2.05%2.53%1 Month Performance-22.63%0.83%3.58%0.93%1 Year Performance-41.61%6.98%30.09%18.70% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.4827 of 5 stars$1.88-2.6%$10.00+431.9%-40.1%$70.56M$52.29M-0.80236MRNAModerna4.6324 of 5 stars$28.09+0.2%$43.59+55.2%-67.1%$10.90B$3.24B-3.735,800Analyst ForecastAVIRAtea Pharmaceuticals1.684 of 5 stars$3.53+0.9%$6.00+70.0%-6.2%$277.75MN/A-2.1970MREOMereo BioPharma Group1.9085 of 5 stars$1.68-3.4%$7.20+328.6%-64.8%$276.66M$10M-24.0040Analyst ForecastGap UpLFCRLifecore Biomedical0.7094 of 5 stars$7.40+0.4%$8.00+8.1%+26.7%$275.70M$128.87M-5.65690DBVTDBV Technologies3.1705 of 5 stars$10.00+0.1%$14.75+47.5%+117.4%$273.62M$4.15M-2.1080High Trading VolumeEDITEditas Medicine4.0447 of 5 stars$2.73-9.9%$5.10+86.8%-27.6%$272.46M$32.31M-0.96230VORVor Biopharma0.4203 of 5 stars$2.04-4.7%N/AN/A$271.10MN/A-0.15140Positive NewsGap UpANNXAnnexon2.9652 of 5 stars$2.35-3.7%$12.50+431.9%-60.8%$267.70MN/A-1.8260NMRANeumora Therapeutics2.2968 of 5 stars$1.64+0.6%$7.14+335.5%-86.1%$263.97MN/A-1.04108Positive NewsALMSAlumis2.8189 of 5 stars$4.85+2.1%$20.17+315.8%-62.1%$258.43MN/A0.00N/A Related Companies and Tools Related Companies Moderna Competitors Atea Pharmaceuticals Competitors Mereo BioPharma Group Competitors Lifecore Biomedical Competitors DBV Technologies Competitors Editas Medicine Competitors Vor Biopharma Competitors Annexon Competitors Neumora Therapeutics Competitors Alumis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access